Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry
Endothelin | Pharmacological Reviews
Reproducing human and cross-species drug toxicities using a Liver-Chip | Science Translational Medicine
CXCL10, a SSc Driver of Inflammation Lowered With Iloprost: Study| Scleroderma News
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry
New Drugs and Emerging Therapeutic Targets in the Endothelin Signaling Pathway and Prospects for Personalized Precision Medicine
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure | EMBO Molecular Medicine
IJMS | Free Full-Text | GPCR Modulation in Breast Cancer
Development of macitentan for the treatment of pulmonary arterial hypertension - Selej - 2015 - Annals of the New York Academy of Sciences - Wiley Online Library
Electronic Medical Records – What I've Learned As A Hospital Medical Director
Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arteri
Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis - John W. McConnell, Yuen Tsang, Janis Pruett, William Drake
PatHligHt
Frontiers | Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension
Reproducing human and cross-species drug toxicities using a Liver-Chip | Science Translational Medicine
Tracleer, INN- bosentan"
NEW ZEALAND DATA SHEET TRACLEER®
NEW ZEALAND DATA SHEET TRACLEER®
Signaling cascades in the failing heart and emerging therapeutic strategies | Signal Transduction and Targeted Therapy
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction | Journal of Medicinal Chemistry
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure | EMBO Molecular Medicine
Janssen CarePath for Healthcare Professionals
